We are live on ! Find out more
LPCN icon

Lipocine
LPCN

30 hedge funds and large institutions have $8.88M invested in Lipocine in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

277% more capital inflows, than outflows

Capital inflows: $1.03M | Capital outflows: $274K

1.12% more ownership

Funds ownership: 11.61% → 12.73% (+1.1%)

6% less funds holding

Funds holding: 32 → 30 (-2)

13% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 8

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

93% less call options, than puts

Call options by funds: $5K | Put options by funds: $76K

Holders
30
Holders Change
-2
Holders Change %
-6.25%
% of All Funds
0.66%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
7
Reduced
8
Closed
6
Calls
$5K
Puts
$76K
Net Calls
-$71K
Net Calls Change
-$52K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$366K
2
Renaissance Technologies
Renaissance Technologies
New York
+$267K
3
Choreo LLC
Choreo LLC
Illinois
+$154K
4
Millennium Management
Millennium Management
New York
+$56.3K
5
QCMA
Quad Capital Management Advisors
New York
+$47.2K

Top Sellers

Rank Fund Capital Flow
1
Mercer Global Advisors
Mercer Global Advisors
Colorado
-$94.5K
2
Panagora Asset Management
Panagora Asset Management
Massachusetts
-$43K
3
Deutsche Bank
Deutsche Bank
Germany
-$34K
4
Spark Investment Management
Spark Investment Management
New York
-$34K
5
Group One Trading
Group One Trading
Illinois
-$22.5K

LPCN Hedge Fund Activity: Q3 2019 in Review

30 of the 4,576 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q3 2019, worth a combined $8.88M — up 60% from $5.56M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of LPCN and 4 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 7 added.

The largest buyer was Vanguard Group, adding an estimated $366K. The largest seller was Mercer Global Advisors, cutting an estimated $94.5K.

  • 30 institutional investors held Lipocine (LPCN) as of Q3 2019, down from 32 in Q2 2019.
  • Funds reported $8.88M of Lipocine stock for Q3 2019, up 60% quarter-over-quarter.
  • 4 funds opened new Lipocine positions in Q3 2019 and 6 closed out, a net change of -2 holders.
  • The largest Lipocine buyer in Q3 2019 was Vanguard Group, an estimated $366K added.
  • The largest Lipocine seller in Q3 2019 was Mercer Global Advisors, an estimated $94.5K sold.

Based on aggregated 13F filings for Q3 2019.